- Academic Editors
-
-
-
Background: This study was carried out to compare the levels of
inflammatory markers in the complete blood count before and after they began
receiving duloxetine in patients with fibromyalgia syndrome (FMS).
Methods: The patient and control groups were composed of 40 patients
diagnosed with FMS in accordance with the 2016 American College of Rheumatology
(ACR) criteria and 40 healthy volunteers, respectively. The data collection tools
comprised the sociodemographic information form, the fibromyalgia impact
questionnaire (FIQ), and the sleep hygiene index (SHI), which were used to assess
patients’ sociodemographic characteristics, FMS disease activity, and sleep
quality, respectively. The inflammatory markers of the patient group were
assessed by complete blood count before and after the duloxetine treatment and
compared with those of the control group. Results: The white blood cell
(WBC), neutrophil, and lymphocyte counts were significantly higher in the patient
group than in the control group (p